Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background Information: Excessive angiogenesis characterized by leaky, tortuous, and chaotic vasculature is one of the hallmarks of cancers and is significantly correlated to poor prognosis. Disorganized angiogenesis leads to poor perfusion of anti-cancer drugs and limits access to immune cells. Hence, impeding angiogenesis is one of the attractive therapeutic targets to inhibit progression and metastasis in several solid tumors including breast. Results:We have developed a robust and reproducible method for isolating and ex vivo culture of endothelial cells (EC) derived from non-malignant (Endo-N) and malignant (Endo-T) part from clinically characterized human breast tumors. RT-PCR and immunoblotting analysis indicated that these cells exhibited expression of endothelial specific genes such as PECAM-1 (CD31), Endoglin (CD105), eNOS, VE-cadherin, VCAM1, and MCAM. Vasculogenic mimicry and contamination of progenitor EC recruited in tumors was ruled out by absence of CD133 expression and normal karyotype. Both the cell types showed stable expression of CD31 and CD105 up to seven passages. Furthermore, compared to Endo-N cells, Endo-T cells showed (a) constitutively increased proliferation marked by nearly 36% of cells in mitotic phase, (b) requirement of glutamine for cell survival, (c) pro-migratory phenotype, (d) produced increased number of sprouts in 3D cultures, and (e) resistance to sorafenib. Conclusion: Tumor derived EC showed distinct biological properties compared to normal breast EC. Significance: Our method for isolating endothelial cell types from human breast tumors may be explored to (a) understand cellular and molecular mechanisms, (b) screen anti-angiogenic molecules, and (c) formulate organoid cultures to develop personalized medicine facilitating better clinical management of breast cancers.
Background Information: Excessive angiogenesis characterized by leaky, tortuous, and chaotic vasculature is one of the hallmarks of cancers and is significantly correlated to poor prognosis. Disorganized angiogenesis leads to poor perfusion of anti-cancer drugs and limits access to immune cells. Hence, impeding angiogenesis is one of the attractive therapeutic targets to inhibit progression and metastasis in several solid tumors including breast. Results:We have developed a robust and reproducible method for isolating and ex vivo culture of endothelial cells (EC) derived from non-malignant (Endo-N) and malignant (Endo-T) part from clinically characterized human breast tumors. RT-PCR and immunoblotting analysis indicated that these cells exhibited expression of endothelial specific genes such as PECAM-1 (CD31), Endoglin (CD105), eNOS, VE-cadherin, VCAM1, and MCAM. Vasculogenic mimicry and contamination of progenitor EC recruited in tumors was ruled out by absence of CD133 expression and normal karyotype. Both the cell types showed stable expression of CD31 and CD105 up to seven passages. Furthermore, compared to Endo-N cells, Endo-T cells showed (a) constitutively increased proliferation marked by nearly 36% of cells in mitotic phase, (b) requirement of glutamine for cell survival, (c) pro-migratory phenotype, (d) produced increased number of sprouts in 3D cultures, and (e) resistance to sorafenib. Conclusion: Tumor derived EC showed distinct biological properties compared to normal breast EC. Significance: Our method for isolating endothelial cell types from human breast tumors may be explored to (a) understand cellular and molecular mechanisms, (b) screen anti-angiogenic molecules, and (c) formulate organoid cultures to develop personalized medicine facilitating better clinical management of breast cancers.
Background Digital mammography (DM) serves as the primary breast imaging technique for early cancer detection and diagnosis. However, it faces certain limitations, particularly in imaging dense breasts. DM exhibits reduced sensitivity and specificity in women with radiographically dense breast tissue due to diminished contrast between potential tumors and surrounding tissue, as well as tissue summation potentially obscuring lesions. The aim of this study was to assess the diagnostic efficacy of digital breast tomosynthesis compared to digital mammography in evaluating suspicious breast lesions. The study included 60 female patients eligible for mammography. All participants underwent full-field digital mammography and 3d tomosynthesis. Written informed consent was obtained from all subjects after explaining the research’s purpose and benefits. The Ethics Committee of the Faculty of Medicine, Menoufia University approved the study under code no. 10/2022RADI24. Results Regarding BIRADS classification: All 60 patients were categorized using the BIRADS lexicon for both mammography and digital breast tomosynthesis. Mammography results showed BIRADS 3 in 10% (6/60), BIRADS 4a in 33.3% (20/60), 4b in 10% (6/60), BIRADS 4c in 26.7% (16/60), and BIRADS 5 in 20% (12/60) of cases. In comparison, tomosynthesis classified cases as BIRADS 3 in 13.3% (8/60), 4b in 16.7% (10/60), BIRADS 4c in 23.3% (14/60), and BIRADS 5 in 46.7% (28/60) of cases. Conclusions Digital breast tomosynthesis (DBT) has established itself as a significant advancement in three-dimensional breast imaging for both screening and diagnostic purposes. It exhibits enhanced performance in identifying breast abnormalities and generates images of superior diagnostic quality with improved precision compared to conventional digital mammography. This improvement is particularly notable when examining dense breast tissue, which has traditionally been one of the most challenging aspects of breast imaging.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.